 Nkarta Inc. NASDAQ: NKTX is up 40 after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hematological malignancies. NKX101 and NKX019 are two leading chimeric antigen receptor natural killer cell therapies the company is developing for two different sets of hematologic malignancies. 